Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer gov’t relations VP

This article was originally published in The Tan Sheet

Executive Summary

Anthony Principi will succeed Kenneth Bowler as Pfizer's VP-government relations, the firm announces March 7. Principi served as secretary of Veterans Affairs under President George Bush and deputy secretary of Veterans Affairs under George H. W. Bush; he spent 10 years in the private sector as president of QTC Medical Services, senior VP at Lockheed Martin IMS and partner at San Diego law firm Luce, Forward, Hamilton & Scripps...

You may also be interested in...



Pfizer Principi departure

Pfizer is seeking a new VP-government affairs following the resignation of Anthony Principi, the firm announces. Principi assumed his post March 15 (1"The Tan Sheet" March 15, 2005, In Brief). Principi headed the company's Washington, D.C. office and is leaving because of the time commitment required to fulfill his duties as chairman of the government's Base Realignment & Closure Commission, Pfizer said. The commission began work May 3. Pfizer Senior VP-Government Relations Richard Bagger, to whom the D.C. office head reports, will assume control of the government affairs staff until a replacement for Principi is found...

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel